VRTX Vertex Pharmaceuticals Stock Outlook 2026: Beyond Trikafta — Three New Bets Ramp
VRTX Vertex Pharmaceuticals stock outlook 2026. Trikafta $2.35B quarterly revenue, Journavx non-opioid pain FDA approved January 30 2025, Casgevy gene therapy 9 countries, inaxaplin APOL1 kidney interim data expected early 2027. Three-scenario valuation for US investors.
VRTX Vertex Pharmaceuticals Trikafta